Menarini Industrie Farmaceutiche Riunite United Kingdom United States of America France Germany Spain Italy New York

Menarini Group Announces Collaboration with VisualDx to Aid in Identifying People Who May Have Blastic Plasmacytoid Dendritic Cell Neoplasm

BPDCN is an aggressive hematologic malignancy with a historically poor prognosisVisualDx is a clinical decision support system used by more than 2,300 hospitals, clinics, and medical schools around the world VisualDx's system seeks to enhance identification of people who may have BPDCN, leveraging actual images of BPDCN skin lesions and artificial intelligence/machine learning (AI/ML) technologies incorporated into the VisualDx platformView original content:https://www.prnewswire.co.uk/news-releases/menarini-group-announces-collaboration-with-visualdx-to-aid-in-identifying-people-who-may-have-blastic-plasmacytoid-dendritic-cell-neoplasm-bpdcn-302407123.html